FibroBiologics, Inc. (FBLG) director reports option stake of 562 shares
Rhea-AI Filing Summary
FibroBiologics, Inc. director Kathleen Hallisey Rubins reported her initial beneficial ownership of a stock option to acquire 562 shares of common stock. The option has a $65.60 exercise price, expires on 2032-09-26, and, according to a footnote, vested over three years and became fully exercisable on September 26, 2025. The option is held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Rubins Kathleen Hallisey
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 562 shares (Direct)
Footnotes (1)
- F1. The options vested over three years and became fully exercisable on September 26, 2025.
Key Figures
Underlying shares: 562 shares
Exercise price: $65.60 per share
Option expiration date: 2032-09-26
+1 more
4 metrics
Underlying shares
562 shares
Common stock underlying the director’s stock option reported on Form 3
Exercise price
$65.60 per share
Exercise price of the reported stock option (Right to Buy)
Option expiration date
2032-09-26
Expiration date of the director’s stock option position
Fully exercisable date
September 26, 2025
Date on which the options became fully exercisable after three-year vesting
Key Terms
Form 3, Stock Option (Right to Buy, exercise price, underlying security
4 terms
Form 3 regulatory
"in an initial Form 3 for FibroBiologics"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)"
exercise price financial
"has a $65.60 exercise price, expires on 2032-09-26"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying security title is Common Stock with 562 shares"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did FibroBiologics (FBLG) director Kathleen Hallisey Rubins report on this Form 3?
Kathleen Hallisey Rubins reported initial beneficial ownership of a stock option to acquire 562 shares of FibroBiologics common stock. The option is held directly and is fully vested, as described in the Form 3 disclosure and related footnote.
What is the exercise price and expiration date of the FBLG director’s stock option?
The reported stock option has an exercise price of $65.60 per share and an expiration date of 2032-09-26. These terms define the cost to exercise the option and the last date on which it can be exercised.
When did the FibroBiologics (FBLG) stock options held by the director become fully exercisable?
According to the footnote, the options vested over three years and became fully exercisable on September 26, 2025. This means that from that date onward, all 562 underlying shares can be purchased under the option terms.
Is this FBLG Form 3 reporting a new transaction or existing holdings?
This Form 3 reports existing holdings of a stock option position rather than a new purchase or sale. The entry is classified as a holding, with no buy or sell transaction code disclosed in the filing data.
How is the FBLG director’s ownership of the stock option characterized?
The stock option is reported as direct ownership by the director. The filing does not attribute the holdings to any trust or entity, indicating the option is held personally rather than indirectly through another organization.